These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24573422)

  • 1. Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology.
    Tsapepas DS; McKeen JT; Martin ST; Walker-McDermott JK; Yang A; Hirsch J; Mohan S; Tiwari R
    J Am Med Inform Assoc; 2014 Oct; 21(e2):e358-62. PubMed ID: 24573422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S
    Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation.
    Gabardi S; Tichy EM
    Prog Transplant; 2013 Mar; 23(1):58-62; quiz 63. PubMed ID: 23448822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing risk in developing transplant immunosuppressive agents: the new regulatory environment.
    Gabardi S; Halloran PF; Friedewald J
    Am J Transplant; 2011 Sep; 11(9):1803-9. PubMed ID: 21827622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations.
    Rostas S; Kim M; Gabardi S
    Prog Transplant; 2014 Mar; 24(1):33-6. PubMed ID: 24598563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.
    Gabardi S
    Prog Transplant; 2013 Mar; 23(1):55-7. PubMed ID: 23448821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk evaluation and mitigation strategies: a focus on belatacept.
    Sam T; Gabardi S; Tichy EM
    Prog Transplant; 2013 Mar; 23(1):64-70. PubMed ID: 23448823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies.
    Kim M; Rostas S; Gabardi S
    Am J Transplant; 2013 Jun; 13(6):1383-9. PubMed ID: 23617812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk evaluation mitigation strategies: the evolution of risk management policy.
    Hollingsworth K; Toscani M
    Popul Health Manag; 2013 Apr; 16(2):132-7. PubMed ID: 23113627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
    Nicholson SC; Peterson J; Yektashenas B
    Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.
    American Pharmacists Association ; Bough M
    J Am Pharm Assoc (2003); 2011; 51(3):340-58. PubMed ID: 21555285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.
    Nicholson S; Peterson J; Yektashenas B
    Expert Opin Drug Saf; 2012 Mar; 11(2):299-314. PubMed ID: 22233294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction.
    Wu J; Juhaeri J
    Clin Ther; 2016 Dec; 38(12):2526-2532. PubMed ID: 27914632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancements in healthcare information technology systems: customizing vendor-supplied clinical decision support for a high-risk patient population.
    Tiwari R; Tsapepas DS; Powell JT; Martin ST
    J Am Med Inform Assoc; 2013; 20(2):377-80. PubMed ID: 22813760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
    Toyserkani GA; Huynh L; Morrato EH
    Front Public Health; 2020; 8():43. PubMed ID: 32158741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.